Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025

• New AA (Allergan Aesthetics) Signature Program provides a personalized approach to treatment planning, in combination with Allergan Aesthetics' advanced facial portfolio to address patient needs and treat different areas of the face
• Expert led Allergan Medical Institute (AMI) symposium will demonstrate how to elevate the patient experience and achieve optimal treatment outcomes using AA Signature program looks
• The Allergan Aesthetics booth offers an immersive experience where healthcare professionals can learn about the product portfolio, the enhanced customer experience and evolution of the AMI Digital World learning platform

NORTH CHICAGO, Ill., Jan. 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, continues to innovate and elevate the patient journey with the launch of its new AA Signature Program at the International Master Course on Aging Science (IMCAS) World Congress 2024 in Paris from January 30 to February 1, 2025. Congress highlights to include the Allergan Medical Institute (AMI) symposium, with a live injection session, Meet the Expert presentations, and an interactive exhibition booth.

Research found that 8 in 10 patients proceed with treatment plans following a holistic consultation¹ and clinics utilizing treatment plans addressing multiple areas of the face see a 68% higher retention rate compared to those that focus on only one area per treatment². The AA Signature Program provides healthcare professionals (HCPs)* with an innovative approach to treatment planning using the Allergan Aesthetics advanced product portfolio to design signature looks for each patient, addressing different patient needs, including lift (added lift, structure and skin firmness), definition (enhanced facial angles and lower face definition) and skin quality (smoother and firmer skin with more hydration).

IMCAS 2025 AMI Symposium

The AMI hosted symposium, 'AA Signatures: Innovating the Patient Journey', will focus on how to design a patient's signature look using the Allergan Aesthetics portfolio of high-quality products, education and support services, through real world examples from experts. A live injection session will be performed from the Allergan Center of Excellence in Italy and will focus specifically on 'lift' from the AA Signature Program, which addresses research finding that sagginess is one of the most undesirable facial features.³

Allergan Aesthetics Medical Symposium Mastering the Lower Face and Neck

On Friday January 31, 2025, Dr. Alexandre Marchac, Dr. Karim Sayed, Dr. Patricia Ogilvie and Dr. Sylwia Lipko-Godlewska will spotlight research and the clinical experience needed to achieve optimal patient outcomes during a panel discussion titled 'Mastering the Lower Face and Neck' which will take place from 08:30 AM – 10:00 AM CET in Room 252, Level 2.

With 1 in 2 people bothered by lines / wrinkles around the lower face⁴, this year's Medical Symposium on 'Mastering the Lower Face and Neck' offers HCPs the support and expertise needed to streamline operations, deepen knowledge and ultimately help advance towards aesthetic excellence in this area.

Meet the Experts

The Meet the Experts sessions on the booth will feature renowned medical professionals, including, Dr. Jean Carruthers who is globally recognized for her pivotal role in the development of today's aesthetic industry. Dr. Jean Carruthers co-wrote the first published paper on the cosmetic use of neuromodulators in 1992 in the Journal of Dermatologic Surgery and Oncology. Dr. Jean Carruthers is credited with discovering the cosmetic use of neuromodulators, which led to the launch of the first neuromodulator in aesthetic medicine: BOTOX^® Cosmetic from Allergan Aesthetics.

Allergan Aesthetics Booth E130, Level 1

The booth will be a discovery hub for exploring the new AA Signature Program, where visitors can get hands-on familiarity with the Allergan Aesthetics portfolio and immerse themselves in the product experience, including: exploring unique product rheology, learning about innovative technologies and practicing injection technique with the guidance of clinical specialists. To continue learning, visitors can join AMI Digital World and access world class education on demand.

Notes to Editors

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com  

Forward-Looking Statements 

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

IMPORTANT SAFETY INFORMATION

BOTOX^® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX^® Cosmetic:

• Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.
• Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

BOTOX^® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX^® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.

BOTOX^® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX^® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not receive BOTOX^® Cosmetic if you are allergic to any of the ingredients in BOTOX^® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX^® Cosmetic.

Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX^® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX^® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX^® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX^® Cosmetic in the past.

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.

Other side effects of BOTOX^® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.

Approved Uses

BOTOX^® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows, and vertical bands connecting the jaw and neck (platysma bands) in adults.

For more information, refer to the Medication Guide or talk with your doctor.

To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.

Please see BOTOX^® Cosmetic full Product Information, including Boxed Warning and Medication Guide.

*AA Signature, by Allergan Aesthetics, is a new program that is launching Internationally at the IMCAS congress in Paris and will be considered for roll out across International markets, as appropriate, over the next year. 

References:

1. Allergan Aesthetics. Data on Ule. REF-115016. HCP Facial Injectables ATU: Neurotoxins—Final Report. January 2022.
2. Humphrey S et al. J Cosmet Dermatol. 2021;20:1495–1498.
3. Allergan Aesthetics. Data on File. The Lower Face Customer & HCP Journey: Qualitative Research Report. May 2024
4. Allergan Aesthetics. Data on File. RES-215748. Consumer and MD Beauty Global Image Research (UD 360 report lower face data). 2019.

View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-unveils-new-aa-signature-program-and-immersive-booth-at-imcas-world-congress-2025-302359301.html

SOURCE AbbVie